WalterMStadlerMD

Genitourinary Oncology, Hematologic Oncology

Fred C. Buffett Professor of Medicine & Surgery, Associate Dean for Clinical Science Research, Clinical Trials Senior Advisor to the Director, UCCCC

Join to view full profile

Dr. Stadler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stadler's full profile

Already have an account?

Office
5841 S. MARYLAND AVE.
M/C 2115
Chicago, IL 60637
Phone+1 773-702-4400

Fax+1 773-702-3163

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1991 - 1994
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1988 - 1991
Yale School of MedicineClass of 1988

Certifications & Licensure

IL State Medical License 1988 - 2026
IN State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly
Chicago Magazine: Top Doctors Castle Connolly
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACP) American College of Physicians, 2002
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Oxaliplatin in Treating Patients With Metastatic Bladder Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 2
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma Start of enrollment: 2000 Jun 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer Start of enrollment: 1999 Aug 01
Completed
Phase 2
SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy Start of enrollment: 2000 Jun 01
Completed
Phase 2
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2000 Oct 01
Completed
Phase 2
PS-341 in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 2
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 1
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2002 Jan 01
Completed
Phase 2
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2002 Oct 01
Completed
Phase 2
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma Start of enrollment: 2003 Oct 01
Terminated
Phase 2
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain Start of enrollment: 2005 Nov 01
Completed
Phase 2
Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2006 May 01
Completed
Phase 2
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23
Active, not recruiting
Phase 1, Phase 2
Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2007 Jul 01
Terminated
Phase 2
A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma Start of enrollment: 2005 Mar 01
Terminated
Phase 2
Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) Start of enrollment: 2009 Jul 01
Completed
Phase 1
A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer Start of enrollment: 2004 Jun 01
Completed
Phase 1
Saracatinib in Treating Patients With Prostate Cancer Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Start of enrollment: 2011 Jan 01
Completed
Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
Completed
Phase 2
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer Start of enrollment: 2012 Jun 01
Terminated
Not Applicable
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Start of enrollment: 2013 Jun 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

122 citations
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
Noura Choudhury, Alexa Campanile, Tatjana Antic, Kai Lee Yap, Carrie Fitzpatrick
Journal of Clinical Oncology. 2016-09-27
157 citations
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
Maha Hussain, Stephanie Daignault-Newton, Przemyslaw Twardowski, Costantine Albany, Mark N. Stein
Journal of Clinical Oncology. 2017-12-20
18 citations
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: resu...
Rahul Aggarwal, Susan Halabi, William Kevin Kelly, Daniel J. George, John Francis Mahoney
Cancer. 2013-10-15

Journal Articles

Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Authored Content

Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic CancersJanuary 2018

Press Mentions

The Caris Precision Oncology Alliance Welcomes University of Chicago Medicine Comprehensive Cancer CenterMarch 8th, 2023
Stand up to Cancer Announces Four Teams Focused on Diversity in Early Phase Cancer Clinical TrialsFebruary 8th, 2023
Myovant’s Phase III Relugolix Trial’s Cardiovascular Event Reduction Trend InconclusiveJune 18th, 2020
Join now to see all

Grant Support

Protocol Review And Monitoring SystemNational Cancer Institute2008–2012
Dynamic-Contrast Enhanced MRI As A BAY 43-9006 MarkerNational Cancer Institute2005–2006
Biomarkers For Bladder Cancer Chemoprevention TrialsNational Cancer Institute1998–1999